As per DelveInsight’s assessment, globally, about 80+ key pharma and biotech companies are working on 80+ pipeline drugs in the Pancreatic Ductal Adenocarcinoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
“Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2024” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Pancreatic Ductal Adenocarcinoma Market.
The Pancreatic Ductal Adenocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Pancreatic Ductal Adenocarcinoma Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Pancreatic Ductal Adenocarcinoma and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Pancreatic Ductal Adenocarcinoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Route of Administration
The Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as:
-
Oral
-
Intravenous
-
Subcutaneous
Molecule Type
Products have been categorized under various Molecule types, such as:
-
Small molecule
-
Cell Therapy
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Pancreatic Ductal Adenocarcinoma Emerging Therapies Mechanism of Action (MOA) Types:
-
Interleukin 8A; 8 receptor antagonist
-
Capillary permeability stimulant
-
Antibody-dependent cell cytotoxicity
-
Ras protein inhibitor stimulant
-
Focal adhesion protein-tyrosine kinase inhibitor
-
Autophagy-related protein-1 homolog inhibitor
-
Polo-like kinase 1 inhibitor
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Learn How the Ongoing Clinical & Commercial Activities will Affect the Pancreatic Ductal Adenocarcinoma Therapeutic Segment @ https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight
Pancreatic Ductal Adenocarcinoma Therapeutics Landscape
Surgical resection and chemotherapy (gemcitabine and FOLFIRINOX, a combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin) has improved the survival of patients with early-stage pancreatic cancer, but these treatments are not sufficient for patients with late stages of the disease). Immunotherapy began a new era in the field of cancer treatment; it is challenging in the context of PDAC as this type of cancer has a nonimmunogenic, immune-suppressive, and therapy-resistant microenvironment. Many molecules currently being tested in clinical trials against PDAC are CCR2, a chemokine receptor that mediates the chemotaxis of immune cells.
There are approx. 80+ key companies developing therapies for Pancreatic Ductal Adenocarcinoma. Currently, XOMA is leading the therapeutics market with its Pancreatic Ductal Adenocarcinoma drug candidates in the most advanced stage of clinical development.
Leading Companies in the Pancreatic Ductal Adenocarcinoma Therapeutics Market Include:
-
Cardiff Oncology
-
XOMA
-
Alphamab
-
Cantargia
-
RenovoRx
-
Syntrix Biosystems
-
Eucure Biopharma
-
Panbela Therapeutics
-
Jeil Pharmaceutical
-
Elicio Therapeutics
-
Cend Therapeutics
-
SignalChem Lifesciences
-
Bristol-Myers Squibb
-
AstraZeneca
-
REVOLUTION Medicines
-
Arcus Biosciences
-
ZielBio
-
Surface Oncology
-
Incyte Corporation
-
I-Mab Biopharma
-
Medicenna Therapeutics
-
Tarveda Therapeutics
-
And Many Others
Pancreatic Ductal Adenocarcinoma Therapies Covered in the Report Include:
-
Onvansertib: Cardiff Oncology
-
Nadunolimab: Cantargia
-
Zimberelimab: Arcus Biosciences
-
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight
Table of Contents
1. Report Introduction
2. Executive Summary
3. Pancreatic Ductal Adenocarcinoma Current Treatment Patterns
4. Pancreatic Ductal Adenocarcinoma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Pancreatic Ductal Adenocarcinoma Late Stage Products (Phase-III)
7. Pancreatic Ductal Adenocarcinoma Mid-Stage Products (Phase-II)
8. Pancreatic Ductal Adenocarcinoma Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pancreatic Ductal Adenocarcinoma Discontinued Products
13. Pancreatic Ductal Adenocarcinoma Product Profiles
14. Key Companies in the Pancreatic Ductal Adenocarcinoma Market
15. Key Products in the Pancreatic Ductal Adenocarcinoma Therapeutics Segment
16. Dormant and Discontinued Products
17. Pancreatic Ductal Adenocarcinoma Unmet Needs
18. Pancreatic Ductal Adenocarcinoma Future Perspectives
19. Pancreatic Ductal Adenocarcinoma Analyst Review
20. Appendix
21. Report Methodology
Related Reports By DelveInsight
Pancreatic Ductal Adenocarcinoma Pipeline Insight
DelveInsight’s “Pancreatic Ductal Adenocarcinoma – Pipeline Insight, 2024,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/